Back to search

Peptide record

TPDB43143

B1-Gln Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB43143
B1-Gln
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
VKRFKKFFRKLKKQV-NH2
Physicochemical Analysis
C96H162N28O17
ANDCEGHIMPSTWY
K
1980.52
12.46
8
0
6
+8
4.33
-1.020
64.67
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
1
Q
0
G
0
H
0
I
1
L
6
K
0
M
3
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 0 L: 1 K: 6 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
15
C96H162N28O17
1980.52
12.46
+8
4.33
-1.020
Amidation
L
Linear
Free
Antimicrobial and Anticancer
Synthetic analog of B1
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 14.5 µM
Anticancer
14.5 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 16.2 µM
Anticancer
16.2 µM

Target

Leukemia cancer
K-562
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015